| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride manufacturers
|
| | N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride Basic information |
| Product Name: | N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride | | Synonyms: | LY 2886721 hydrochloride salt;LY 2886721 hydrochloride;N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride;N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride | | CAS: | 1262036-49-6 | | MF: | C18H16F2N4O2S.HCl | | MW: | 426.8679864 | | EINECS: | | | Product Categories: | | | Mol File: | 1262036-49-6.mol | ![N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride Structure](CAS/GIF/1262036-49-6.gif) |
| | N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO|42.69|100| |
| | N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride Usage And Synthesis |
| Uses | LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment[1]. | | in vivo | LY2886721 hydrochloride (3-30 mg/kg; oral administration; PDAPP mice) treatment significantly reduces the hippocampal and cortical levels of Aβ1-x. LY2886721 hydrochloride treatment results in significant reduction of brain parenchymal levels of C99 and sAPPβ[1]. | | storage | Store at -20°C | | References | [1] May PC1, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210. DOI:10.1523/JNEUROSCI.4129-14.2015 |
| | N-[3-[(4aS,7aS)-2-Amino-5,7-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(4aH)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide hydrochloride Preparation Products And Raw materials |
|